Shopping Cart
Remove All
Your shopping cart is currently empty
LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. It can cross the blood-brain barrier and is applicable in studying synucleinopathies.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. It can cross the blood-brain barrier and is applicable in studying synucleinopathies. |
| In vitro | LETC inhibits α-synuclein aggregation in DH60.21 neuroblastoma cells that have been transfected, with an EC50 of 66 nM. |
| In vivo | LETC (10 mg/kg; oral administration; 5 days per week; for 6 weeks) significantly reduces α-Syn-positive neurons in various brain regions, thereby alleviating motor deficits in these mice during open field tests. However, LETC does not improve activity deficits in L62 mice within their home cage environment. Following oral administration in α-Syn transgenic L62 mice, LETC accumulates in the brain with a half-life of approximately 6 hours. |
| Molecular Weight | 414.43 |
| Formula | C20H29Cl2N3S |
| Cas No. | 951131-13-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.